An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme.

Trial Profile

An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Olaratumab (Primary) ; Ramucirumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top